34 results on '"Debatin, Km"'
Search Results
2. Editorial Expression of Concern: Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells.
- Author
-
Ehrhardt H, Häcker S, Wittmann S, Maurer M, Borkhardt A, Toloczko A, Debatin KM, Fulda S, and Jeremias I
- Subjects
- Humans, Neoplasms drug therapy, Neoplasms genetics, Neoplasms pathology, Antineoplastic Agents pharmacology, Gene Expression Regulation, Neoplastic drug effects, Apoptosis drug effects, Tumor Suppressor Protein p53 metabolism, Tumor Suppressor Protein p53 genetics, Caspase 8 metabolism, Caspase 8 genetics, Up-Regulation drug effects
- Published
- 2024
- Full Text
- View/download PDF
3. CHD5 inhibits metastasis of neuroblastoma.
- Author
-
Laut AK, Dorneburg C, Fürstberger A, Barth TFE, Kestler HA, Debatin KM, and Beltinger C
- Subjects
- Humans, Cell Line, Tumor, Animals, Mice, Gene Expression Regulation, Neoplastic, Neoplasm Invasiveness genetics, Nerve Tissue Proteins, Neuroblastoma genetics, Neuroblastoma pathology, Neuroblastoma metabolism, DNA Helicases genetics, DNA Helicases metabolism, Neoplasm Metastasis, Cell Movement genetics
- Abstract
CHD5, a tumor suppressor at 1p36, is frequently lost or silenced in poor prognosis neuroblastoma (NB) and many adult cancers. The role of CHD5 in metastasis is unknown. We confirm that low expression of CHD5 is associated with stage 4 NB. Forced expression of CHD5 in NB cell lines with 1p loss inhibited key aspects of the metastatic cascade in vitro: anchorage-independent growth, migration, and invasion. In vivo, formation of bone marrow and liver metastases developing from intravenously injected NB cells was delayed and decreased by forced CHD5 expression. Genome-wide mRNA sequencing revealed reduction of genes and gene sets associated with metastasis when CHD5 was overexpressed. Known metastasis-suppressing genes preferentially upregulated in CHD5-overexpressing NB cells included PLCL1. In patient NB, low expression of PLCL1was associated with metastatic disease and poor survival. Knockdown of PLCL1 and of p53 in IMR5 NB cells overexpressing CHD5 reversed CHD5-induced inhibition of invasion and migration in vitro. In summary, CHD5 is a metastasis suppressor in NB., (© 2021. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
4. Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner.
- Author
-
Wagner L, Marschall V, Karl S, Cristofanon S, Zobel K, Deshayes K, Vucic D, Debatin KM, and Fulda S
- Subjects
- Apoptosis physiology, Apoptosis Regulatory Proteins, Biomimetic Materials administration & dosage, Brain Neoplasms metabolism, Brain Neoplasms pathology, Cell Line, Tumor, Dacarbazine administration & dosage, Dacarbazine pharmacology, Down-Regulation, Drug Synergism, Glioblastoma metabolism, Glioblastoma pathology, Humans, Inhibitor of Apoptosis Proteins biosynthesis, Inhibitor of Apoptosis Proteins genetics, Oligopeptides administration & dosage, Prognosis, Temozolomide, Antineoplastic Combined Chemotherapy Protocols pharmacology, Apoptosis drug effects, Biomimetic Materials pharmacology, Brain Neoplasms drug therapy, Dacarbazine analogs & derivatives, Glioblastoma drug therapy, Intracellular Signaling Peptides and Proteins metabolism, Mitochondrial Proteins metabolism, NF-kappa B metabolism, Nuclear Pore Complex Proteins metabolism, Oligopeptides pharmacology, RNA-Binding Proteins metabolism
- Abstract
Inhibitor of apoptosis (IAP) proteins are expressed at high levels in many cancers and therefore represent attractive targets for therapeutic intervention. Here, we report for the first time that the second mitochondria-derived activator of caspases (Smac) mimetic BV6 sensitizes glioblastoma cells toward Temozolomide (TMZ), the first-line chemotherapeutic agent in the treatment of glioblastoma. BV6 and TMZ synergistically reduce cell viability and trigger apoptosis in glioblastoma cells (combination index <0.4-0.8), which is accompanied by increased loss of mitochondrial-membrane potential, cytochrome c release, caspase activation and caspase-dependent apoptosis. Analysis of the molecular mechanisms reveals that BV6 causes rapid degradation of cIAP1, leading to stabilization of NF-κB-inducing kinase and NF-κB activation. BV6-stimulated NF-κB activation is critically required for sensitization toward TMZ, as inhibition of NF-κB by overexpression of the mutant IκBα super-repressor profoundly reduces loss of mitochondrial membrane potential, cytochrome c release, caspase activation and apoptosis. Of note, BV6-mediated sensitization to TMZ is not associated with increased tumor necrosis factor alpha (TNFα) production. Also, TNFα, CD95 or TRAIL-blocking antibodies or knockdown of TNFR1 have no or little effect on combination treatment-induced apoptosis. Interestingly, BV6 and TMZ cooperate to trigger the formation of a RIP1 (receptor activating protein 1)/caspase-8/FADD complex. Knockdown of RIP1 by small interfering RNA significantly reduces BV6- and TMZ-induced caspase-8 activation and apoptosis, showing that RIP1 is necessary for apoptosis induction. By demonstrating that BV6 primes glioblastoma cells for TMZ in a NF-κB- and RIP1-dependent manner, these findings build the rationale for further (pre)clinical development of Smac mimetics in combination with TMZ.
- Published
- 2013
- Full Text
- View/download PDF
5. Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP.
- Author
-
Bangert A, Cristofanon S, Eckhardt I, Abhari BA, Kolodziej S, Häcker S, Vellanki SH, Lausen J, Debatin KM, and Fulda S
- Subjects
- CASP8 and FADD-Like Apoptosis Regulating Protein metabolism, Caspases metabolism, Cell Line, Tumor, Cell Membrane Permeability drug effects, Cell Proliferation drug effects, Enzyme Activation drug effects, Gene Expression Regulation, Neoplastic drug effects, Humans, Mitochondrial Membranes drug effects, Mitochondrial Membranes metabolism, Receptors, Death Domain metabolism, TNF-Related Apoptosis-Inducing Ligand pharmacology, Apoptosis drug effects, CASP8 and FADD-Like Apoptosis Regulating Protein genetics, Glioblastoma genetics, Glioblastoma metabolism, Histone Deacetylase Inhibitors pharmacology, Proto-Oncogene Proteins c-myc metabolism, TNF-Related Apoptosis-Inducing Ligand metabolism
- Abstract
Glioblastoma is the most common primary brain tumor with a very poor prognosis, calling for novel treatment strategies. Here, we provide first evidence that histone deacetylase inhibitors (HDACI) prime glioblastoma cells for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) -induced apoptosis at least in part by c-myc-mediated downregulation of cellular FLICE-inhibitory protein (cFLIP). Pretreatment with distinct HDACI (MS275, suberoylanilide hydroxamic acid, valproic acid) significantly enhances TRAIL-induced apoptosis in several glioblastoma cell lines. Monitoring a panel of apoptosis-regulatory proteins revealed that MS275 reduces the expression of cFLIP(L) and cFLIP(S). This leads to decreased recruitment of cFLIP(L) and cFLIP(S) and increased activation of caspase-8 to the TRAIL death-inducing signaling complex, resulting in enhanced cleavage of caspase-8, -9 and -3 and caspase-dependent apoptosis. Also, MS275 promotes TRAIL-triggered processing of Bid, activation of Bax, loss of mitochondrial membrane potential and release of cytochrome c. MS275-mediated downregulation of cFLIP occurs at the mRNA level independent of proteasome- or caspase-mediated degradation, and is preceded by upregulation of nuclear levels of c-myc, a transcriptional repressor of cFLIP. Notably, MS275 causes increased binding of c-myc to the cFLIP promoter and reduces cFLIP promoter activity. Indeed, knockdown of c-myc partially rescues cFLIP(L) from MS275-inferred downregulation and significantly decreases TRAIL- and MS275-induced apoptosis. Also, overexpression of cFLIP(L) or cFLIP(S) significantly reduces MS275- and TRAIL-induced apoptosis. Importantly, MS275 sensitizes primary cultured glioblastoma cells towards TRAIL and cooperates with TRAIL to reduce long-term clonogenic survival of glioblastoma cells and to suppress glioblastoma growth in vivo underscoring the clinical relevance of this approach. Thus, these findings demonstrate that HDACI represent a promising strategy to prime glioblastoma for TRAIL-induced apoptosis by targeting cFLIP.
- Published
- 2012
- Full Text
- View/download PDF
6. Identification of a novel pro-apoptotic role of NF-κB in the regulation of TRAIL- and CD95-mediated apoptosis of glioblastoma cells.
- Author
-
Jennewein C, Karl S, Baumann B, Micheau O, Debatin KM, and Fulda S
- Subjects
- Animals, Caspases, Cell Line, Tumor, Humans, Mice, NF-kappa B antagonists & inhibitors, Transcriptional Activation, Apoptosis drug effects, Brain Neoplasms metabolism, Glioblastoma metabolism, NF-kappa B physiology, TNF-Related Apoptosis-Inducing Ligand metabolism, fas Receptor metabolism
- Abstract
We recently reported that nuclear factor-kappa B (NF-κB) promotes DNA damage-triggered apoptosis in glioblastoma, the most common brain tumor. In the present study, we investigated the role of NF-κB in death receptor-mediated apoptosis. Here, we identify a novel pro-apopotic function of NF-κB in TRAIL- and CD95-induced apoptosis. Inhibition of NF-κB by overexpression of the dominant-negative IκBα-superrepressor (IκBα-SR) significantly decreases tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)- or CD95-induced apoptosis. Vice versa, activation of NF-κB via overexpression of constitutively active IκB kinase complex (IKK)β (IKK-EE) significantly increases TRAIL-mediated apoptosis. Intriguingly, NF-κB inhibition reduces the recruitment of Fas-associated death domain and caspase-8 and formation of the death-inducing signaling complex (DISC) upon stimulation of TRAIL receptors or CD95. This results in reduced TRAIL-mediated activation of caspases, loss of mitochondrial potential and cytochrome c release in IκBα-SR-expressing cells. In comparison, NF-κB inhibition strongly enhances TNF-α-mediated apoptosis. Comparative studies revealed that TNF-α rapidly stimulates transcriptional activation and upregulation of anti-apoptotic proteins, whereas TRAIL causes apoptosis before transcriptional activation. Thus, this study demonstrates for the first time that NF-κB exerts a pro-apoptotic role in TRAIL- and CD95-induced apoptosis in glioblastoma cells by facilitating DISC formation.
- Published
- 2012
- Full Text
- View/download PDF
7. Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation.
- Author
-
Häcker S, Karl S, Mader I, Cristofanon S, Schweitzer T, Krauss J, Rutkowski S, Debatin KM, and Fulda S
- Subjects
- Humans, Medulloblastoma pathology, Antineoplastic Agents pharmacology, Apoptosis drug effects, Histone Deacetylase Inhibitors pharmacology, Medulloblastoma drug therapy, Tumor Suppressor Protein p53 metabolism, bcl-2-Associated X Protein metabolism
- Abstract
Despite aggressive therapies, the prognosis of children with high-risk medulloblastoma is still poor, thus underscoring the need to develop novel treatment strategies. Here, we report that histone deacetylase inhibitors (HDACI), that is, MS-275, valproic acid or SAHA, provide a novel strategy for sensitization of medulloblastoma to DNA-damaging drugs such as Doxorubicin, VP16 and Cisplatin by promoting p53-dependent, mitochondrial apoptosis. Mechanistic studies reveal that single-agent treatment with MS-275 causes acetylation of the non-histone protein Ku70, an event reported to release Bax from Ku70, whereas DNA-damaging drugs trigger p53 acetylation and accumulation. Combined treatment with MS-275 and Doxorubicin or VP16 cooperates to promote binding of p53 to Bax and p53-dependent Bax activation, resulting in enhanced loss of mitochondrial membrane potential, cytochrome c release and caspase-dependent apoptosis. Overexpression of Bcl-2 almost completely abolishes the MS-275-mediated chemosensitization, underlining the importance of the mitochondrial pathway for inducing apoptosis. Also, MS-275 cooperates with chemotherapeutics to inhibit long-term clonogenic survival. Most importantly, MS-275 increases chemotherapeutic drug-induced apoptosis in primary medulloblastoma samples, and cooperates with Doxorubicin to suppress medulloblastoma growth in an in vivo model, which underscores the clinical relevance of the findings. Thus, HDACI such as MS-275 present a promising approach for chemosensitization of medulloblastoma by enhancing mitochondrial apoptosis in a p53-dependent manner. These findings have important clinical implications for the design of experimental treatment protocols for medulloblastoma.
- Published
- 2011
- Full Text
- View/download PDF
8. PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis.
- Author
-
Bender A, Opel D, Naumann I, Kappler R, Friedman L, von Schweinitz D, Debatin KM, and Fulda S
- Subjects
- Apoptosis physiology, Blotting, Western, Brain Neoplasms drug therapy, Cell Line, Tumor, Cell Separation, Doxorubicin pharmacology, Drug Synergism, Flow Cytometry, Furans pharmacokinetics, Humans, Immunoprecipitation, Mitochondria drug effects, Neuroblastoma drug therapy, Phosphoinositide-3 Kinase Inhibitors, Proto-Oncogene Proteins c-bcl-2 metabolism, Pyridines pharmacokinetics, Pyrimidines pharmacokinetics, RNA, Small Interfering, Signal Transduction drug effects, Signal Transduction physiology, Transfection, Antineoplastic Agents pharmacology, Apoptosis drug effects, Brain Neoplasms metabolism, Enzyme Inhibitors pharmacology, Neuroblastoma metabolism, Proto-Oncogene Proteins c-bcl-2 drug effects
- Abstract
We recently identified activation of phosphatidylinositol 3'-kinase (PI3K)/Akt as a novel predictor of poor outcome in neuroblastoma. Here, we investigated the effect of small-molecule PI3K inhibitors on chemosensitivity. We provide first evidence that PI3K inhibitors, for example PI103, synergize with various chemotherapeutics (Doxorubicin, Etoposide, Topotecan, Cisplatin, Vincristine and Taxol) to trigger apoptosis in neuroblastoma cells (combination index: high synergy). Mechanistic studies reveal that PI103 cooperates with Doxorubicin to reduce Mcl-1 expression and Bim(EL) phosphorylation and to upregulate Noxa and Bim(EL) levels. This shifted ratio of pro- and antiapoptotic Bcl-2 proteins results in increased Bax/Bak conformational change, loss of mitochondrial membrane potential, cytochrome c release, caspase activation and caspase-dependent apoptosis. Although Mcl-1 knockdown enhances Doxorubicin- and PI103-induced apoptosis, silencing of Noxa, Bax/Bak or p53 reduces apoptosis, underscoring the functional relevance of the Doxorubicin- and PI103-mediated modulation of these proteins for chemosensitization. Bcl-2 overexpression inhibits Bax activation, mitochondrial perturbations, cleavage of caspases and Bid, and apoptosis, confirming the central role of the mitochondrial pathway for chemosensitization. Interestingly, the broad-range caspase inhibitor zVAD.fmk does not interfere with Bax activation or mitochondrial outer membrane permeabilization, whereas it blocks caspase activation and apoptosis, thus placing mitochondrial events upstream of caspase activation. Importantly, PI103 and Doxorubicin cooperate to induce apoptosis and to suppress tumor growth in patients' derived primary neuroblastoma cells and in an in vivo neuroblastoma model, underlining the clinical relevance of the results. Thus, targeting PI3K presents a novel and promising strategy to sensitize neuroblastoma cells for chemotherapy-induced apoptosis, which has important implications for the development of targeted therapies for neuroblastoma.
- Published
- 2011
- Full Text
- View/download PDF
9. The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair.
- Author
-
Westhoff MA, Kandenwein JA, Karl S, Vellanki SH, Braun V, Eramo A, Antoniadis G, Debatin KM, and Fulda S
- Subjects
- Cell Line, Tumor, Chromones pharmacology, DNA Damage, DNA-Activated Protein Kinase physiology, Doxorubicin pharmacology, Glioblastoma pathology, Histones genetics, Humans, Morpholines pharmacology, Phosphatidylinositol 3-Kinases physiology, Signal Transduction drug effects, Antineoplastic Agents pharmacology, Apoptosis drug effects, DNA Repair drug effects, Furans pharmacology, Glioblastoma drug therapy, Phosphoinositide-3 Kinase Inhibitors, Pyridines pharmacology, Pyrimidines pharmacology
- Abstract
The failure of conventional therapies in glioblastoma (GBM) is largely due to an aberrant activity of survival cascades, such as PI3 kinase (PI3K)/Akt-mediated signaling. This study is the first to show that the class I PI3K inhibitor, PI-103, enhances chemotherapy-induced cell death of GBM cells. Concurrent treatment with PI-103 and DNA-damaging drugs, in particular doxorubicin, significantly increases apoptosis and reduces colony formation compared with chemotherapy treatment alone. The underlying molecular mechanism for this chemosensitization was shown by two independent approaches, that is, pharmacological and genetic inhibition of PI3K, DNA-PK and mTOR, to involve inhibition of DNA-PK-mediated DNA repair. Accordingly, blockage of PI3K or DNA-PK, but not of mTOR, significantly delays the resolution of doxorubicin-induced DNA damage and concomitantly increases apoptosis. Importantly, not only are several GBM cell lines chemosensitized by PI-103 but also GBM stem cells. Clinical relevance was further confirmed by the use of primary cultured GBM cells, which also exhibit increased cell death and reduced colony formation on combined treatment with PI-103 and doxorubicin. By identifying class I PI3K inhibitors as powerful agents in enhancing the lethality of DNA-damaging drugs, to which GBMs are usually considered unresponsive, our findings have important implications for the design of rational combination regimens in overcoming the frequent chemoresistance of GBM.
- Published
- 2009
- Full Text
- View/download PDF
10. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
- Author
-
Häcker S, Dittrich A, Mohr A, Schweitzer T, Rutkowski S, Krauss J, Debatin KM, and Fulda S
- Subjects
- Benzamides pharmacology, Caspase 8 genetics, Cell Line, Tumor, Cell Survival drug effects, Cerebellar Neoplasms, Drug Combinations, Enzyme Inhibitors classification, Enzyme Inhibitors pharmacology, Gene Expression Regulation, Enzymologic, Gene Silencing, Heterozygote, Humans, Hydroxamic Acids pharmacology, Medulloblastoma, Neoplasms, Pyridines pharmacology, TNF-Related Apoptosis-Inducing Ligand genetics, Time Factors, Valproic Acid pharmacology, Vorinostat, Caspase 8 metabolism, Drug Resistance, Neoplasm drug effects, Histone Deacetylase Inhibitors, Interferon-gamma pharmacology, TNF-Related Apoptosis-Inducing Ligand pharmacology
- Abstract
Evasion of apoptosis can be caused by epigenetic silencing of caspase-8, a key component of the extrinsic apoptosis pathway. Loss of caspase-8 correlates with poor prognosis in medulloblastoma, which highlights the relevance of strategies to upregulate caspase-8 to break apoptosis resistance. Here, we develop a new combinatorial approach, that is treatment using histone deacetylase inhibitors (HDACI) together with interferon (IFN)-gamma, to restore caspase-8 expression and to overcome resistance to the death-receptor ligand TNF-related apoptosis-inducing ligand (TRAIL) in medulloblastoma in vitro and in vivo. HDACI, for example, valproic acid (VA), suberoylanilide hydroxamic acid (SAHA) and MS-275, cooperate with IFN-gamma to upregulate caspase-8 in cancer cells lacking caspase-8, thereby restoring sensitivity to TRAIL-induced apoptosis. Molecular studies show that VA promotes histone acetylation and acts in concert with IFN-gamma to stimulate caspase-8 promoter activity. The resulting increase in caspase-8 mRNA and protein expression leads to enhanced TRAIL-induced activation of caspase-8 at the death-inducing signaling complex, mitochondrial outer-membrane permeabilization and caspase-dependent cell death. Intriguingly, pharmacological or genetic inhibition of caspase-8 also abolishes the VA/IFN-gamma-mediated sensitization for TRAIL-induced apoptosis. It is important to note that VA and IFN-gamma restore caspase-8 expression and sensitivity to TRAIL in primary medulloblastoma samples and significantly potentiate TRAIL-mediated suppression of medulloblastoma growth in vivo. These findings provide the rationale for further (pre)clinical evaluation of VA and IFN-gamma to restore caspase-8 expression and apoptosis sensitivity in cancers with caspase-8 silencing and open new perspectives to overcome TRAIL resistance.
- Published
- 2009
- Full Text
- View/download PDF
11. Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells.
- Author
-
Westhoff MA, Zhou S, Bachem MG, Debatin KM, and Fulda S
- Subjects
- Antineoplastic Agents pharmacology, Apoptosis drug effects, Brain Neoplasms genetics, Brain Neoplasms metabolism, Cell Cycle, Cell Line, Tumor, Extracellular Matrix Proteins metabolism, Glioblastoma genetics, Glioblastoma metabolism, Humans, Signal Transduction, Brain Neoplasms pathology, Cell Adhesion genetics, Drug Resistance, Neoplasm, Glioblastoma pathology
- Abstract
The failure of malignant cells to undergo apoptosis is a major obstacle in cancer therapy, and thus identifying the underlining molecules involved therein is imperative for improving patient survival. An important mechanism of drug resistance is cell adhesion-mediated drug resistance (CAM-DR). In this study we identify a novel switch by which glioblastoma multiforme (GBM) cells alter the mode of CAM-DR. In the absence of a microenvironmental cue provided by components of the extracellular matrix (ECM), GBM cells are able to employ an alternative, but equally effective, mode of CAM-DR by forming spheres via cell-cell interactions. Intriguingly, when inhibiting cell-cell interactions in the absence of ECM components, either by low cell density or by inhibition of gap junctions (intercellular connexin tunnels) through chemical inhibition with carbenoxyolone or co-incubation with the connexin-mimicking Gap 27 Cx37,43 peptide, GBM cells were sensitized to tumor necrosis factor-related apoptosis-inducing ligand- and CD95-induced apoptosis. By demonstrating that GBM cells can alternate from one form of CAM-DR (cell-substrate tethering) to another (homocellular cell-cell adhesion) and that inhibition of both forms is necessary for apoptosis sensitization, our findings not only have important implications for novel approaches to restore defective apoptosis programs, but also reveal a novel role of gap junctions in GBM.
- Published
- 2008
- Full Text
- View/download PDF
12. N-myc augments death and attenuates protective effects of Bcl-2 in trophically stressed neuroblastoma cells.
- Author
-
Ushmorov A, Hogarty MD, Liu X, Knauss H, Debatin KM, and Beltinger C
- Subjects
- Blotting, Western, CASP8 and FADD-Like Apoptosis Regulating Protein metabolism, Caspase Inhibitors, Caspases metabolism, Cell Survival physiology, Culture Media, Serum-Free pharmacology, Gene Expression Regulation, Neoplastic, Glycolysis, Humans, Inhibitor of Apoptosis Proteins, Microtubule-Associated Proteins antagonists & inhibitors, Microtubule-Associated Proteins genetics, Microtubule-Associated Proteins metabolism, Neoplasm Proteins antagonists & inhibitors, Neoplasm Proteins genetics, Neoplasm Proteins metabolism, Neuroblastoma genetics, Neuroblastoma pathology, Phenotype, Phosphorylation, Protein Transport, Proto-Oncogene Proteins c-myc genetics, RNA, Messenger genetics, RNA, Messenger metabolism, Retroviridae genetics, Reverse Transcriptase Polymerase Chain Reaction, Survivin, Tamoxifen analogs & derivatives, Tamoxifen pharmacology, Tumor Cells, Cultured, Apoptosis physiology, Neuroblastoma metabolism, Oxidative Stress, Proto-Oncogene Proteins c-bcl-2 metabolism, Proto-Oncogene Proteins c-myc metabolism
- Abstract
N-myc has proapoptotic functions, yet it acts as an oncogene in neuroblastoma. Thus, antiapoptotic mechanisms have to be operative in neuroblastoma cells that antagonize the proapoptotic effects of N-myc. We conditionally activated N-myc in SH-EP neuroblastoma cells subjected to the trophic stress of serum or nutrient deprivation while changing the expression of Bcl-2, survivin and FLIP(L), antiapoptotic molecules often overexpressed in poor prognosis neuroblastomas. Bcl-2 protected SH-EP cells from death during nutritional deprivation by activating energetically advantageous oxidative phosphorylation. N-myc overrode the metabolic protection provided by Bcl-2-induced oxidative phosphorylation by reestablishing the glycolytic phenotype and attenuated the antiapoptotic effect of Bcl-2 during metabolic stress. Survivin partially antagonized the growth suppressive function of N-myc in SH-EP neuroblastoma cells during serum deprivation whereas FLIP(L) did not. These findings advance our understanding of the functions of N-myc in neuroblastoma cells.
- Published
- 2008
- Full Text
- View/download PDF
13. Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells.
- Author
-
Ehrhardt H, Häcker S, Wittmann S, Maurer M, Borkhardt A, Toloczko A, Debatin KM, Fulda S, and Jeremias I
- Subjects
- Caspase 8 genetics, Caspase Inhibitors, Cell Line, Tumor, Humans, RNA, Messenger metabolism, TNF-Related Apoptosis-Inducing Ligand pharmacology, Tumor Suppressor Protein p53 antagonists & inhibitors, Tumor Suppressor Protein p53 genetics, Up-Regulation, Antineoplastic Agents pharmacology, Apoptosis drug effects, Caspase 8 metabolism, Drug Resistance, Neoplasm, Fluorouracil pharmacology, Methotrexate pharmacology, Tumor Suppressor Protein p53 metabolism
- Abstract
Apoptosis resistance is crucially involved in cancer development and progression, represents the leading cause for failure of anticancer therapy and is caused, for example, by downregulation of proapoptotic intracellular signaling molecules such as caspase-8. We found that the cytotoxic drugs methotrexate (MTX) and 5-fluorouracil (5-FU) were both able to sensitize resistant tumor cells for induction of apoptosis by p53-mediated upregulation of caspase-8. Increase in caspase-8 messenger RNA and protein expression disabled tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced proliferation and restored sensitivity toward TRAIL-induced apoptosis which was inhibited by transfection of p53 decoy oligonucleotides, p53 shRNA and caspase-8 shRNA. Upregulation of caspase-8 and sensitization toward TRAIL-induced apoptosis was found both in a broad panel of tumor cell lines with downregulated caspase-8 and in TRAIL-resistant primary tumor cells of children with acute leukemia. Taken together, we have identified caspase-8 as an important p53 target gene regulated by cytotoxic drugs. These findings highlight a new drug-induced modulation of physiological apoptosis pathways, which may be involved in successful anticancer therapy using MTX and 5-FU in leukemia and solid tumors over decades.
- Published
- 2008
- Full Text
- View/download PDF
14. Sensitization of pancreatic carcinoma cells for gamma-irradiation-induced apoptosis by XIAP inhibition.
- Author
-
Giagkousiklidis S, Vellanki SH, Debatin KM, and Fulda S
- Subjects
- Blotting, Western, Caspases metabolism, Enzyme Activation radiation effects, Humans, Membrane Potential, Mitochondrial radiation effects, Pancreatic Neoplasms metabolism, Pancreatic Neoplasms pathology, RNA, Small Interfering pharmacology, Tumor Cells, Cultured metabolism, Tumor Cells, Cultured radiation effects, X-Linked Inhibitor of Apoptosis Protein genetics, X-Linked Inhibitor of Apoptosis Protein metabolism, Apoptosis radiation effects, Gamma Rays, Pancreatic Neoplasms radiotherapy, Radiation Tolerance physiology, X-Linked Inhibitor of Apoptosis Protein antagonists & inhibitors
- Abstract
Resistance of pancreatic cancer to current treatments including radiotherapy remains a major challenge in oncology and may be caused by defects in apoptosis programs. Since 'inhibitor of apoptosis proteins' (IAPs) block apoptosis at the core of the apoptotic machinery by inhibiting caspases, therapeutic modulation of IAPs could tackle a key resistance mechanism. Here, we report that targeting X-linked inhibitor of apoptosis (XIAP) by RNA-interference-mediated knockdown or overexpression of second mitochondria-derived activator of caspase significantly enhanced apoptosis and markedly reduced clonogenic growth of pancreatic carcinoma cells upon gamma-irradiation. Analysis of signaling pathways revealed that antagonizing XIAP increased activation of caspase-2, -3, -8 and -9 and loss of mitochondrial membrane potential upon gamma-irradiation. Interestingly, inhibition of caspases also reduced the cooperative effect of XIAP targeting and gamma-irradiation to trigger mitochondrial perturbations, suggesting that XIAP controls a feedback mitochondrial amplification loop by regulating caspase activity. Importantly, our data demonstrate for the first time that small molecule XIAP inhibitors sensitized pancreatic carcinoma cells for gamma-irradiation-induced apoptosis, whereas they had no effect on gamma-irradiation-mediated apoptosis of non-malignant fibroblasts indicating some tumor specificity. In conclusion, targeting XIAP, for example by small molecules, is a promising novel approach to enhance radiosensitivity of pancreatic cancer that warrants further investigation.
- Published
- 2007
- Full Text
- View/download PDF
15. Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance.
- Author
-
Kilic M, Kasperczyk H, Fulda S, and Debatin KM
- Subjects
- Apoptosis Regulatory Proteins genetics, Apoptosis Regulatory Proteins metabolism, Baculoviral IAP Repeat-Containing 3 Protein, Cells, Cultured, Fructose-Bisphosphate Aldolase genetics, Fructose-Bisphosphate Aldolase metabolism, Glucose metabolism, Glucose Transporter Type 1 metabolism, Humans, Hypoxia metabolism, Hypoxia-Inducible Factor 1 antagonists & inhibitors, Hypoxia-Inducible Factor 1 genetics, Inhibitor of Apoptosis Proteins genetics, Inhibitor of Apoptosis Proteins metabolism, Proto-Oncogene Proteins c-bcl-2 genetics, Proto-Oncogene Proteins c-bcl-2 metabolism, RNA, Small Interfering pharmacology, Ubiquitin-Protein Ligases, Apoptosis genetics, Glucose Transporter Type 1 genetics, Hypoxia genetics, Hypoxia-Inducible Factor 1 physiology
- Abstract
Hypoxia inducible factor-1 (HIF-1) is the major transcription factor and key regulator of adoptive responses to hypoxia. Although it usually promotes tumor cell survival under hypoxia, it has also been implied to trigger apoptosis. Although the impact of hypoxia has been extensively studied in many adult solid tumors, its role in most childhood tumors, for example, in rhabdomyosarcoma (RMS) or Ewing sarcoma (ES), has not yet been addressed. Here, we report that hypoxia protects A204 RMS and A673 ES cells against anticancer drug- or tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis and that Hif-1alpha plays a key role in conferring apoptosis resistance under hypoxia. Although a functional HIF-1 pathway and proapoptotic proteins such as p53 and Bcl-2/E1B 19 kDa interacting protein 3 were activated under hypoxia in both A204 RMS and A673 ES cells, these cells remained refractory to apoptosis. Concomitant analysis of antiapoptotic proteins revealed that hypoxia induced expression of Bcl-2 and inhibitor of apoptosis proteins (IAP)-2 as well as proteins associated with anaerobic metabolism such as the glucose transporter protein GLUT-1 and the glycolytic enzyme Aldolase A. Specific downregulation of Hif-1alpha by RNA interference significantly enhanced apoptosis under hypoxia by preventing the hypoxia-mediated increase in GLUT-1 expression without altering expression levels of the antiapoptotic proteins Bcl-2 or cIAP-2. Moreover, glucose deprivation-induced apoptosis of A204 RMS and A673 ES cells was inhibited under hypoxic conditions in a Hif-1alpha-dependent manner. As GLUT-1 was induced via Hif-1alpha under hypoxia in A204 RMS and A673 ES, these findings suggest that the Hif-1alpha-mediated increase in glucose uptake plays an important role in conferring apoptosis resistance. Thus, hypoxia-inducible genes may represent novel targets for therapeutic intervention in some pediatric tumors, which warrants further investigation.
- Published
- 2007
- Full Text
- View/download PDF
16. NF-kappaB-independent sensitization of glioblastoma cells for TRAIL-induced apoptosis by proteasome inhibition.
- Author
-
La Ferla-Brühl K, Westhoff MA, Karl S, Kasperczyk H, Zwacka RM, Debatin KM, and Fulda S
- Subjects
- Active Transport, Cell Nucleus drug effects, Cell Nucleus metabolism, DNA-Binding Proteins metabolism, Doxorubicin pharmacology, Drug Resistance, Neoplasm, Humans, Leupeptins pharmacology, NF-kappa B antagonists & inhibitors, NF-kappa B metabolism, Transcriptional Activation drug effects, Tumor Cells, Cultured, Apoptosis drug effects, Glioblastoma pathology, NF-kappa B physiology, Proteasome Inhibitors, TNF-Related Apoptosis-Inducing Ligand pharmacology
- Abstract
The transcription factor nuclear factor-kappaB (NF-kappaB) is a key regulator of stress-induced transcriptional activation and has been implicated in mediating primary or acquired apoptosis resistance in various cancers. In the present study, we therefore investigated the role of NF-kappaB in regulating apoptosis in malignant glioma, a prototypic tumor refractory to current treatment approaches. Here, we report that constitutive NF-kappaB DNA-binding activity was low or moderate in eight different glioblastoma cell lines compared to Hodgkin's lymphoma cells, known to harbor aberrant constitutive NF-kappaB activity. Specific inhibition of NF-kappaB by overexpression of inhibitor of kappaB (IkappaB)alpha superrepressor did not enhance spontaneous apoptosis of glioblastoma cells. Also, overexpression of IkappaBalpha superrepressor had no significant impact on apoptosis induced by two prototypic classes of apoptotic stimuli, that is, chemotherapeutic drugs or death-inducing ligands such as TNF-related apoptosis inducing ligand (TRAIL), which are known to trigger NF-kappaB activation as part of a cellular stress response. Similarly, inhibition of NF-kappaB by the proteasome inhibitor MG132 did not increase doxorubicin (Doxo)-induced apoptosis of glioblastoma cells, although it prevented DNA binding of NF-kappaB complexes in response to Doxo. Interestingly, proteasome inhibition significantly sensitized glioblastoma cells for TRAIL-induced apoptosis. These findings indicate that the characteristic antiapoptotic function of NF-kappaB reported for many cancers is not a primary feature of glioblastoma and thus, specific NF-kappaB inhibition may not be effective for chemosensitization of glioblastoma. Instead, proteasome inhibitors, which enhanced TRAIL-induced apoptosis in an NF-kappaB-independent manner, may open new perspectives to increase the efficacy of TRAIL-based regimens in glioblastoma, which warrants further investigation.
- Published
- 2007
- Full Text
- View/download PDF
17. Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells.
- Author
-
Vogler M, Dürr K, Jovanovic M, Debatin KM, and Fulda S
- Subjects
- Caspases, Effector metabolism, Cytochromes c metabolism, Humans, Ligands, Membrane Potential, Mitochondrial, Pancreatic Neoplasms pathology, Receptors, TNF-Related Apoptosis-Inducing Ligand metabolism, Retroviridae genetics, Transfection, Tumor Cells, Cultured, Tumor Stem Cell Assay, X-Linked Inhibitor of Apoptosis Protein antagonists & inhibitors, X-Linked Inhibitor of Apoptosis Protein genetics, Apoptosis, Pancreatic Neoplasms metabolism, TNF-Related Apoptosis-Inducing Ligand pharmacology, X-Linked Inhibitor of Apoptosis Protein metabolism
- Abstract
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a promising candidate for cancer therapy because of its relative tumor selectivity. However, many cancers including pancreatic cancer remain resistant towards TRAIL. To develop TRAIL for cancer therapy of pancreatic carcinoma, it will therefore be pivotal to elucidate the molecular mechanisms of TRAIL resistance. Here, we identify X-linked inhibitor of apoptosis (XIAP) as a regulator of TRAIL sensitivity in pancreatic carcinoma cells. Full activation of effector caspases, loss of mitochondrial membrane potential and cytochrome c release following TRAIL treatment were markedly impaired in pancreatic carcinoma cell lines, which poorly responded to TRAIL (PaTuII, PancTu1, ASPC1, DanG), compared to TRAIL-sensitive Colo357 pancreatic carcinoma cells. Stable downregulation of XIAP by RNA interference significantly reduced survival and enhanced TRAIL-induced apoptosis in pancreatic carcinoma cells. Also, downregulation of XIAP significantly increased CD95-induced cell death. Importantly, knockdown of XIAP strongly inhibited clonogenicity of pancreatic cancer cells treated with TRAIL indicating that XIAP promotes clonogenic survival of pancreatic carcinoma cells. Thus, our findings for the first time indicate that targeting XIAP represents a promising strategy to enhance the antitumor activity of TRAIL in pancreatic cancer, which has important clinical implications.
- Published
- 2007
- Full Text
- View/download PDF
18. 5-Aza-2'-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8.
- Author
-
Fulda S and Debatin KM
- Subjects
- Apoptosis Regulatory Proteins genetics, Apoptosis Regulatory Proteins pharmacology, Azacitidine pharmacology, Caspase 8, Caspases deficiency, Caspases metabolism, Cell Line, Tumor, Cell Survival drug effects, Cerebellar Neoplasms, Decitabine, Gene Expression Regulation, Enzymologic, Humans, Medulloblastoma, Membrane Glycoproteins genetics, Membrane Glycoproteins pharmacology, Neuroblastoma, Recombinant Proteins pharmacology, TNF-Related Apoptosis-Inducing Ligand, Tumor Necrosis Factor-alpha genetics, Tumor Necrosis Factor-alpha pharmacology, Apoptosis drug effects, Apoptosis Regulatory Proteins physiology, Azacitidine analogs & derivatives, Caspases genetics, Interferon-gamma pharmacology, Membrane Glycoproteins physiology, Tumor Necrosis Factor-alpha physiology
- Abstract
Resistance of tumors to cytotoxic therapy remains a major obstacle in cancer treatment and is often caused by defects in apoptosis programs. Caspase-8, a key mediator of death receptor-induced apoptosis, has previously been reported to be frequently inactivated by epigenetic silencing in many tumors, for example in neuroblastoma or medulloblastoma. Here, we provide for the first time evidence that combined treatment with suboptimal concentrations of the demethylating agent 5-Aza-2'-deoxycytidine (5-dAzaC) and interferon-gamma (IFN-gamma) cooperated to upregulate caspase-8 expression in neuroblastoma and medulloblastoma cells lacking caspase-8. Consequently, activation of caspase-8 and downstream caspases upon addition of TNF-related apoptosis-inducing ligand (TRAIL) was restored by pretreatment with 5-dAzaC and IFN-gamma. Importantly, pretreatment with 5-dAzaC and IFN-gamma acted in concert to significantly enhance TRAIL-induced apoptosis in neuroblastoma and medulloblastoma cells. Inhibition of caspase-8 by dominant-negative caspase-8 or by the relatively specific caspase-8 inhibitior zIETD.fmk inhibited the increase in apoptosis provided by 5-dAzaC and IFN-gamma, indicating that caspase-8 is a key mediator of this sensitization effect. Thus, by demonstrating that 5-dAzaC and IFN-gamma at relatively low individual concentrations cooperate to restore caspase-8 expression and sensitize resistant neuroblastoma and medulloblastoma cells to TRAIL-induced apoptosis, our findings have important implications for novel strategies targeting defective apoptosis pathways in neuroectodermal tumors.
- Published
- 2006
- Full Text
- View/download PDF
19. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy.
- Author
-
Fulda S and Debatin KM
- Subjects
- Animals, Antineoplastic Agents therapeutic use, Humans, Neoplasms pathology, Signal Transduction, Antineoplastic Agents pharmacology, Apoptosis drug effects, Neoplasms drug therapy
- Abstract
Apoptosis or programmed cell death is a key regulator of physiological growth control and regulation of tissue homeostasis. One of the most important advances in cancer research in recent years is the recognition that cell death mostly by apoptosis is crucially involved in the regulation of tumor formation and also critically determines treatment response. Killing of tumor cells by most anticancer strategies currently used in clinical oncology, for example, chemotherapy, gamma-irradiation, suicide gene therapy or immunotherapy, has been linked to activation of apoptosis signal transduction pathways in cancer cells such as the intrinsic and/or extrinsic pathway. Thus, failure to undergo apoptosis may result in treatment resistance. Understanding the molecular events that regulate apoptosis in response to anticancer chemotherapy, and how cancer cells evade apoptotic death, provides novel opportunities for a more rational approach to develop molecular-targeted therapies for combating cancer.
- Published
- 2006
- Full Text
- View/download PDF
20. Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity.
- Author
-
Vogler M, Giagkousiklidis S, Genze F, Gschwend JE, Debatin KM, and Fulda S
- Subjects
- Antibiotics, Antineoplastic pharmacology, Apoptosis Regulatory Proteins, Blotting, Western, Carcinoma metabolism, Carcinoma pathology, Caspases metabolism, Cell Count, Cell Cycle, Cell Division drug effects, Cell Line, Tumor, Cell Movement drug effects, Colonic Neoplasms metabolism, Colonic Neoplasms pathology, Cytosol metabolism, Doxorubicin pharmacology, Glioblastoma metabolism, Glioblastoma pathology, Humans, Intracellular Signaling Peptides and Proteins pharmacology, Mitochondria metabolism, Mitochondrial Proteins genetics, Mitochondrial Proteins pharmacology, Neuroblastoma metabolism, Neuroblastoma pathology, Pancreatic Neoplasms metabolism, Pancreatic Neoplasms pathology, Proteins antagonists & inhibitors, X-Linked Inhibitor of Apoptosis Protein antagonists & inhibitors, beta-Galactosidase metabolism, Apoptosis drug effects, Cell Proliferation drug effects, Cell Survival drug effects, Gene Expression Regulation, Neoplastic drug effects, Intracellular Signaling Peptides and Proteins metabolism, Mitochondrial Proteins metabolism
- Abstract
While second mitochondria derived activator of caspase (Smac) has been described to sensitize for apoptosis, its effect on cell viability in the absence of apoptotic stimuli has remained unclear. Here, we report that Smac inhibits clonogenic tumor growth by blocking random migration and proliferation and by enhancing apoptosis in a cell density and cell type dependent manner in SH-EP neuroblastoma cells. Inhibition of clonogenic survival by overexpression of full-length or processed Smac strictly depended on low cell density, and was reversible by replatement at high density. We discovered that Smac inhibits cell motility and random migration at low cell density. In addition, Smac enhanced apoptosis and inhibited protein, but not mRNA expression of XIAP, survivin and other short-lived proteins (FLIP, p21), indicating that Smac may globally inhibit protein expression. Also, Smac inhibited proliferation and increased polynucleation with no evidence for polyploidy, cell cycle arrest or senescence indicating that Smac impaired cell division. Interestingly, inhibition of clonogenic capacity by Smac occurred independent of its apoptosis promoting activity. By demonstrating that Smac restrains clonogenic tumor growth, our findings may have important implications for control of tumor growth and/or its metastatic spread. Thus, Smac agonists may be useful in cancer therapy, for example, for tumor control in minimal residual disease. Oncogene (2005) 24, 7190-7202. doi:10.1038/sj.onc.1208876; published online 8 August 2005., (Oncogene (2005) 24, 7190-7202. doi:10.1038/sj.onc.1208876; published online 8 August 2005.)
- Published
- 2005
- Full Text
- View/download PDF
21. Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy.
- Author
-
Kasperczyk H, La Ferla-Brühl K, Westhoff MA, Behrend L, Zwacka RM, Debatin KM, and Fulda S
- Subjects
- Apoptosis, Base Sequence, Cell Line, Tumor, DNA Primers, Humans, Hydrolysis, I-kappa B Proteins metabolism, NF-KappaB Inhibitor alpha, Pentacyclic Triterpenes, Betulinic Acid, NF-kappa B metabolism, Neoplasms therapy, Triterpenes pharmacology
- Abstract
Recent evidence demonstrates that the anticancer activity of betulinic acid (BetA) can be markedly increased by combination protocols, for example with chemotherapy, ionizing radiation or TRAIL. Since nuclear factor-kappaB (NF-kappaB), a key regulator of stress-induced transcriptional activation, has been implicated in mediating apoptosis resistance, we investigated the role of NF-kappaB in BetA-induced apoptosis. Here, we provide for the first time evidence that BetA activates NF-kappaB in a variety of tumor cell lines. NF-kappaB DNA-binding complexes induced by BetA consisted of p50 and p65 subunits. Nuclear translocation of p65 was also confirmed by immunofluorescence microscopy. BetA-induced NF-kappaB activation involved increased IKK activity and phosphorylation of IkappaB-alpha at serine 32/36 followed by degradation of IkappaB-alpha. Reporter assays revealed that NF-kappaB activated by BetA is transcriptionally active. Interestingly, inhibition of BetA-induced NF-kappaB activation by different chemical inhibitors (proteasome inhibitor, antioxidant, IKK inhibitor) attenuated BetA-induced apoptosis. Importantly, specific NF-kappaB inhibition by transient or stable expression of IkappaB-alpha super-repressor inhibited BetA-induced apoptosis in SH-EP neuroblastoma cells, while transient expression of IkappaB-alpha super-repressor had no influence on BetA-induced apoptosis in two other cell lines. Thus, our findings that activation of NF-kappaB by BetA promotes BetA-induced apoptosis in a cell type-specific fashion indicate that NF-kappaB inhibitors in combination with BetA would have no therapeutic benefit or could even be contraproductive in certain tumors, which has important implications for the design of BetA-based combination protocols.
- Published
- 2005
- Full Text
- View/download PDF
22. Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis.
- Author
-
Mohr A, Zwacka RM, Jarmy G, Büneker C, Schrezenmeier H, Döhner K, Beltinger C, Wiesneth M, Debatin KM, and Stahnke K
- Subjects
- Caspase 8, Hematopoietic Stem Cells immunology, Humans, NK Cell Lectin-Like Receptor Subfamily D, Antigens, CD physiology, Antigens, CD34 immunology, Apoptosis physiology, Caspases metabolism, Hematopoietic Stem Cells cytology, Lectins, C-Type physiology, Leukemia pathology
- Abstract
Regulation of sensitivity or resistance for apoptosis by death receptor ligand systems is a key control mechanism in the hematopoietic system. Dysfunctional or deregulated apoptosis can potentially contribute to the development of immune deficiencies, autoimmune diseases, and leukemia. Control of homeostasis starts at the level of hematopoietic stem cells (HSC). To this end, we found that CD34+ hematopoietic progenitor cells are constitutively resistant to CD95-mediated apoptosis and cannot be sensitized during short-term culture to death receptor-mediated apoptosis by cytokines. Detailed analysis of the death machinery revealed that CD34+ cells do not express caspase-8a/b, a crucial constituent of the death-inducing signaling complex (DISC) of death receptors. Instead, we found a smaller splice variant termed caspase-8L to be present in HSC. Forced expression of caspase-8L using a recombinant lentiviral vector was able to protect hematopoietic cells from death receptor-induced apoptosis even in the presence of caspase-8a/b. Furthermore, we found that caspase-8L is recruited to the DISC after CD95 triggering, thereby preventing CD95 from connecting to the caspase cascade. These results demonstrate an antiapoptotic function of caspase-8L and suggest a critical role as apoptosis regulator in HSC. Similar to CD34+ HSC, stem cell-derived leukemic blasts from AML(M0) patients only expressed caspase-8L. Additionally we found, caspase-8L expression in several AML and ALL samples. Thus, caspase-8L expression might explain constitutive resistance to CD95-mediated apoptosis in CD34+ progenitor cells and might participate in the development of stem cell-derived and other leukemias by providing protection from regulatory apoptosis.
- Published
- 2005
- Full Text
- View/download PDF
23. Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells.
- Author
-
Fulda S, Jeremias I, and Debatin KM
- Subjects
- Anti-Inflammatory Agents, Non-Steroidal pharmacology, Apoptosis drug effects, Apoptosis Regulatory Proteins, Cell Division drug effects, Cell Line, Tumor, Cell Survival drug effects, Humans, Intracellular Membranes physiology, Kidney Neoplasms, Medulloblastoma, Melanoma, Membrane Glycoproteins metabolism, Membrane Potentials physiology, Mitochondria physiology, Neuroblastoma, Pentacyclic Triterpenes, Proto-Oncogene Proteins c-bcl-2 genetics, TNF-Related Apoptosis-Inducing Ligand, Tumor Necrosis Factor-alpha metabolism, Betulinic Acid, Apoptosis physiology, Membrane Glycoproteins genetics, Triterpenes pharmacology, Tumor Necrosis Factor-alpha genetics
- Abstract
We previously reported that the TRAIL (tumor necrosis factor (TNF)-related apoptosis-inducing ligand)-induced death signal requires amplification by mitochondria in certain cell types, for example, in type II cells. Here, we provide for the first time evidence that the natural compound betulinic acid (BetA) cooperated with TRAIL to induce apoptosis in tumor cells. Through functional complementation, simultaneous stimulation of the death receptor pathway by TRAIL and the mitochondrial pathway by BetA resulted in complete activation of effector caspases, apoptosis and inhibition of clonogenic survival. BetA and TRAIL cooperated to trigger loss of mitochondrial membrane potential and release of cytochrome c and Smac from mitochondria. Also, combination treatment with BetA and TRAIL resulted in increased cleavage of caspase-8 and Bid indicating that activation of effector caspases may feed back in a positive amplification loop. Importantly, the combination treatment with BetA and TRAIL cooperated to induce apoptosis in different tumor cell lines and also in primary tumor cells, but not in normal human fibroblasts indicating some tumor specificity. Since most human cancers represent type II cells, triggering the mitochondrial pathway by BetA may be a novel approach to enhance the efficacy of TRAIL-based therapies, which warrants further investigation.
- Published
- 2004
- Full Text
- View/download PDF
24. Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol.
- Author
-
Fulda S and Debatin KM
- Subjects
- Cell Cycle drug effects, Cell Division drug effects, Cell Line, Tumor, Humans, Inhibitor of Apoptosis Proteins, Jurkat Cells, Microtubule-Associated Proteins genetics, Neoplasm Proteins, RNA, Messenger drug effects, RNA, Messenger genetics, Resveratrol, Reverse Transcriptase Polymerase Chain Reaction, Survivin, Anticarcinogenic Agents toxicity, Antineoplastic Agents toxicity, Apoptosis drug effects, Stilbenes toxicity
- Abstract
Current attempts to improve the survival of cancer patients largely depend on strategies to target tumor cell resistance. Naturally occurring dietary compounds such as resveratrol have gained considerable attention as cancer chemopreventive agents. Here, we report that resveratrol acts as potent sensitizer for anticancer drug-induced apoptosis by inducing cell cycle arrest, which in turn resulted in survivin depletion. Concomitant analysis of cell cycle and apoptosis revealed that pretreatment with resveratrol resulted in cell cycle arrest in S phase and apoptosis induction preferentially out of S phase upon subsequent drug treatment. Likewise, cell cycle arrest in S phase by cell cycle inhibitors enhanced drug-induced apoptosis. Resveratrol-mediated cell cycle arrest sensitized for apoptosis by downregulating survivin expression through transcriptional and post-transcriptional mechanisms. Similarly, downregulation of survivin expression using survivin antisense oligonucleotides sensitized for drug-induced apoptosis. Importantly, downregulation of survivin and enhanced drug-induced apoptosis by resveratrol occurred in various human tumor cell lines irrespective of p53 status. Thus, this combined sensitizer (resveratrol)/inducer (cytotoxic drugs) concept may be a novel strategy to enhance the efficacy of anticancer therapy in a variety of human cancers.
- Published
- 2004
- Full Text
- View/download PDF
25. Death receptors in chemotherapy and cancer.
- Author
-
Debatin KM and Krammer PH
- Subjects
- Animals, CASP8 and FADD-Like Apoptosis Regulating Protein, Carrier Proteins physiology, Caspases physiology, Fas Ligand Protein, Humans, NF-kappa B metabolism, Neoplasms pathology, Prognosis, Receptors, TNF-Related Apoptosis-Inducing Ligand, Receptors, Tumor Necrosis Factor physiology, Signal Transduction, Apoptosis, Intracellular Signaling Peptides and Proteins, Membrane Glycoproteins physiology, Neoplasms drug therapy, fas Receptor physiology
- Abstract
Apoptosis, the cell's intrinsic death program, is a key regulator of tissue homeostasis. An imbalance between cell death and proliferation may result in tumor formation. Also, killing of cancer cells by cytotoxic therapies such as chemotherapy, gamma-irradiation or ligation of death receptors is predominantly mediated by triggering apoptosis in target cells. In addition to the intrinsic mitochondrial pathway, elements of death receptor signaling pathways have been implied to contribute to the efficacy of cancer therapy. Failure to undergo apoptosis in response to anticancer therapy may lead to resistance. Also, deregulated expression of death receptor pathway molecules may contribute to tumorigenesis and tumor escape from endogenous growth control. Understanding the molecular events that regulate apoptosis induced by anticancer therapy and how cancer cells evade apoptosis may provide new opportunities for pathway-based rational therapy and for drug development.
- Published
- 2004
- Full Text
- View/download PDF
26. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB.
- Author
-
Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, and Jeremias I
- Subjects
- Acute Disease, Adolescent, Apoptosis Regulatory Proteins, Cell Division drug effects, Cell Survival drug effects, Child, Child, Preschool, Cysteine Endopeptidases metabolism, Drug Resistance, Neoplasm, Female, Humans, I-kappa B Kinase, Jurkat Cells drug effects, Leukemia, Myeloid pathology, Male, Multienzyme Complexes metabolism, Protease Inhibitors pharmacology, Proteasome Endopeptidase Complex, Protein Serine-Threonine Kinases deficiency, Protein Serine-Threonine Kinases physiology, Proteins physiology, Receptor-Interacting Protein Serine-Threonine Kinases, TNF-Related Apoptosis-Inducing Ligand, Tumor Cells, Cultured drug effects, Antineoplastic Agents pharmacology, Apoptosis drug effects, Membrane Glycoproteins pharmacology, NF-kappa B physiology, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology, Tumor Necrosis Factor-alpha pharmacology
- Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in cancer cells. Examining primary cells of children with untreated acute leukemia, TRAIL induced apoptosis in 50% of cells, but to our surprise attenuated spontaneous apoptosis in the remaining samples or, most importantly, even mediated proliferation. We therefore examined tumor cell lines of leukemic and nonleukemic origin with apoptosis resistance towards TRAIL because of absent Caspase-8 or dysfunctional FADD. In all cell lines tested, TRAIL treatment increased cell numbers in average to 163% within 4 days and accelerated doubling time from 24 to 19 h. TRAIL-mediated proliferation was completely abrogated by blockade of NF-kappaB activation using proteasome inhibitors or in RIP-negative, IKKgamma-negative cells or in cells overexpressing dominant-negative IkappaBalpha. Our data describe the biological significance of TRAIL-mediated activation of NF-kappaB in cancer cells resistant to TRAIL-mediated apoptosis: TRAIL leads to an increase in tumor cell count by a prosurvival and possibly mitogenic function. Given the promising therapeutic potential of TRAIL as a novel anticancer drug, TRAIL-mediated survival or proliferation of target cells may restrict its use to apoptosis-sensitive tumors.
- Published
- 2003
- Full Text
- View/download PDF
27. Chemotherapy: targeting the mitochondrial cell death pathway.
- Author
-
Debatin KM, Poncet D, and Kroemer G
- Subjects
- Animals, Intracellular Membranes drug effects, Mice, Antineoplastic Agents pharmacology, Apoptosis drug effects, Mitochondria drug effects
- Abstract
One of the mechanisms by which chemotherapeutics destroy cancer cells is by inducing apoptosis. Apoptosis can be activated through several different signalling pathways, but these all appear to converge at a single event - mitochondrial membrane permeabilization (MMP). This 'point-of-no-return' in the cell death program is a complex process that is regulated by the composition of the mitochondrial membrane and pre-mitochondrial signal-transduction events. MMP is subject to a complex regulation, and local alterations in the composition of mitochondrial membranes, as well as alterations in pre-mitochondrial signal-transducing events, can determine chemotherapy resistance in cancer cells. Detecting MMP might thus be useful for detecting chemotherapy responses in vivo. Several cytotoxic drugs induce MMP by a direct action on mitochondria. This type of agents can enforce death in cells in which upstream signals normally leading to apoptosis have been disabled. Cytotoxic components acting on mitochondria can specifically target proteins from the Bcl-2 family, the peripheral benzodiazepin receptor, or the adenine nucleotide translocase, and/or act by virtue of their physicochemical properties as steroid analogues, cationic ampholytes, redox-active compounds or photosensitizers. Some compounds acting on mitochondria can overcome the cytoprotective effect of Bcl-2-like proteins. Several agents which are already used in anti-cancer chemotherapy can induce MMP, and new drugs specifically designed to target mitochondria are being developed.
- Published
- 2002
- Full Text
- View/download PDF
28. IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway.
- Author
-
Fulda S and Debatin KM
- Subjects
- Apoptosis Regulatory Proteins, Caspase 8, Caspase 9, Caspases genetics, DNA Methylation, DNA, Neoplasm metabolism, DNA-Binding Proteins metabolism, Drug Resistance, Neoplasm, Drug Synergism, Humans, Membrane Glycoproteins pharmacology, Mitochondria drug effects, Mitochondria metabolism, Neoplasms genetics, Neoplasms pathology, RNA, Neoplasm biosynthesis, STAT1 Transcription Factor, Signal Transduction, TNF-Related Apoptosis-Inducing Ligand, Trans-Activators metabolism, Transcriptional Activation, Tumor Cells, Cultured, Tumor Necrosis Factor-alpha pharmacology, Up-Regulation, Antineoplastic Agents pharmacology, Apoptosis, Caspases biosynthesis, Interferon-gamma pharmacology, Neoplasms metabolism
- Abstract
Resistance of tumors to cytotoxic therapy may be due to disrupted apoptosis programs and remains a major obstacle in cancer treatment. Here, we report that IFNgamma sensitizes resistant tumor cells with absent or low caspase-8 expression for apoptosis induced by death-inducing ligands or cytotoxic drugs by upregulating caspase-8 through a Stat1/IRF1 dependent pathway. Combined treatment using IFNgamma with TRAIL, APO1, TNFalpha or cytotoxic drugs cooperated to trigger apoptosis in various resistant tumor cell lines derived from Ewing tumor, neuroblastoma or medulloblastoma, while single agents exerted only a minimal effect. Importantly, IFNgamma induced caspase-8 expression also in cells with inactivation of the caspase-8 gene by hypermethylation, although no direct effect of IFNgamma on the methylation status of regulatory sequences of the caspase-8 gene was found. IFNgamma-mediated facilitation of apoptosis was inhibited by the caspase-8 specific inhibitor zIETD.fmk or in caspase-8 mutant Jurkat cells implying a prominent role of caspase-8 in mediating sensitization by IFNgamma. Upregulation of caspase-8 and sensitization for apoptosis by IFNgamma was blocked by overexpression of dominant-negative mutants of Stat1 or in Stat1-deficient U3A cells, while complementation of Stat1-deficient U3A cells with wild-type Stat1 restored the IFNgamma effect. Moreover, ectopic expression of IRF1 induced caspase-8 expression thereby sensitizing cells for TRAIL-, APO1- or doxorubicin-induced apoptosis. These findings provide evidence that the Stat1/IRF1 pathway is involved in induction of caspase-8 expression and apoptosis initiated by IFNgamma and indicate that IFNgamma might be an effective strategy to sensitize various resistant tumor cells with deficient caspase-8 expression for chemotherapy- or death receptor-induced apoptosis.
- Published
- 2002
- Full Text
- View/download PDF
29. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression.
- Author
-
Fulda S, Meyer E, and Debatin KM
- Subjects
- Apoptosis Regulatory Proteins, Breast Neoplasms metabolism, Breast Neoplasms pathology, Caspases metabolism, Central Nervous System Neoplasms metabolism, Central Nervous System Neoplasms pathology, Female, Glioblastoma metabolism, Glioblastoma pathology, Humans, Kinetics, Mitochondria metabolism, Neoplasms pathology, Neuroblastoma metabolism, Neuroblastoma pathology, Proteins genetics, Proteins metabolism, Proto-Oncogene Proteins c-bcl-2 genetics, TNF-Related Apoptosis-Inducing Ligand, Transfection, Tumor Cells, Cultured, X-Linked Inhibitor of Apoptosis Protein, Apoptosis, Membrane Glycoproteins antagonists & inhibitors, Neoplasms metabolism, Proto-Oncogene Proteins c-bcl-2 metabolism, Tumor Necrosis Factor-alpha antagonists & inhibitors
- Abstract
Primary or acquired resistance to current treatment protocols remains a major concern in clinical oncology and may be caused by defects in apoptosis programs. Since recent data suggest that TRAIL can bypass apoptosis resistance caused by Bcl-2, we further investigated the role of Bcl-2 in TRAIL-induced apoptosis. Here we report that overexpression of Bcl-2 conferred protection against TRAIL in neuroblastoma, glioblastoma or breast carcinoma cell lines. Bcl-2 overexpression reduced TRAIL-induced cleavage of caspase-8 and Bid indicating that caspase-8 was activated upstream and also downstream of mitochondria in a feedback amplification loop. Importantly, Bcl-2 blocked cleavage of caspases-9, -7 and -3 into active subunits and cleavage of the caspase substrates DFF45 or PARP. Also, Bcl-2 blocked cleavage of XIAP and overexpression of XIAP conferred resistance against TRAIL indicating that apoptosis was also amplified through a feedforward loop between caspases and XIAP. In contrast, in SKW lymphoblastoid cells, TRAIL-induced activation of caspase-8 directly translated into full activation of caspases, cleavage of XIAP, DFF45 or PARP and apoptosis independent of Bcl-2 overexpression, although Bcl-2 similarly inhibited loss of mitochondrial membrane potential and the release of cytochrome c, AIF and Smac from mitochondria in all cell types. By demonstrating a cell type dependent regulation of the TRAIL signaling pathway at different level, e.g. by Bcl-2 and by XIAP, these findings may have important clinical implication. Thus, strategies targeting the molecular basis of resistance towards TRAIL may be necessary in some tumors for cancer therapy with TRAIL.
- Published
- 2002
- Full Text
- View/download PDF
30. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer.
- Author
-
Fulda S, Küfer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, and Debatin KM
- Subjects
- Apoptosis, Apoptosis Regulatory Proteins, Azacitidine analogs & derivatives, Azacitidine pharmacology, Bone Neoplasms drug therapy, Caspase 3, Caspase 8, Caspase 9, Caspases genetics, DNA Modification Methylases pharmacology, Decitabine, Down-Regulation, Enzyme Induction drug effects, Gene Transfer Techniques, Humans, Methylation, Neoplasm Proteins genetics, RNA, Messenger metabolism, Receptors, Tumor Necrosis Factor metabolism, Sarcoma, Ewing drug therapy, TNF-Related Apoptosis-Inducing Ligand, Tumor Cells, Cultured, Bone Neoplasms metabolism, Caspases metabolism, Drug Resistance, Neoplasm physiology, Membrane Glycoproteins pharmacology, Neoplasm Proteins metabolism, Sarcoma, Ewing metabolism, Tumor Necrosis Factor-alpha pharmacology
- Abstract
Resistance of tumors to treatment with cytotoxic drugs, irradiation or immunotherapy may be due to disrupted apoptosis programs. Here, we report in a variety of different tumor cells including Ewing tumor, neuroblastoma, malignant brain tumors and melanoma that caspase-8 expression acts as a key determinant of sensitivity for apoptosis induced by death-inducing ligands or cytotoxic drugs. In tumor cell lines resistant to TRAIL, anti-CD95 or TNFalpha, caspase-8 protein and mRNA expression was decreased or absent without caspase-8 gene loss. Methylation-specific PCR revealed hypermethylation of caspase-8 regulatory sequences in cells with impaired caspase-8 expression. Treatment with the demethylation agent 5-Aza-2'-deoxycytidine (5-dAzaC) reversed hypermethylation of caspase-8 resulting in restoration of caspase-8 expression and recruitment and activation of caspase-8 at the CD95 DISC upon receptor cross-linking thereby sensitizing for death receptor-, and importantly, also for drug-induced apoptosis. Inhibition of caspase-8 activity also inhibited apoptosis sensitization by 5-dAzaC. Similar to demethylation, introduction of caspase-8 by gene transfer sensitized for apoptosis induction. Hypermethylation of caspase-8 was linked to reduced caspase-8 expression in different tumor cell lines in vitro and, most importantly, also in primary tumor samples. Thus, these findings indicate that re-expression of caspase-8, e.g. by demethylation or caspase-8 gene transfer, might be an effective strategy to restore sensitivity for chemotherapy- or death receptor-induced apoptosis in various tumors in vivo.
- Published
- 2001
- Full Text
- View/download PDF
31. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis.
- Author
-
Fulda S, Meyer E, Friesen C, Susin SA, Kroemer G, and Debatin KM
- Subjects
- Amino Acid Chloromethyl Ketones pharmacology, BH3 Interacting Domain Death Agonist Protein, Blotting, Western, Bongkrekic Acid pharmacology, Caspase Inhibitors, Caspases metabolism, Cysteine Proteinase Inhibitors pharmacology, Cytochrome c Group metabolism, Drug Resistance, Fas-Associated Death Domain Protein, Gene Expression drug effects, Humans, Membrane Potentials, Mutation, Proto-Oncogene Proteins c-bcl-2 genetics, Proto-Oncogene Proteins c-bcl-2 metabolism, Proto-Oncogene Proteins c-bcl-2 physiology, Signal Transduction physiology, Tumor Cells, Cultured drug effects, bcl-X Protein, Adaptor Proteins, Signal Transducing, Antineoplastic Agents pharmacology, Apoptosis drug effects, Carrier Proteins metabolism, Doxorubicin pharmacology, Jurkat Cells drug effects, Mitochondria metabolism, fas Receptor metabolism
- Abstract
Apoptosis in response to cellular stress such as treatment with cytotoxic drugs is mediated by effector caspases (caspase-3) which can be activated by different initiator pathways. Here, we report on a cell type specific triggering of death receptor and/or mitochondrial pathways upon drug treatment. In type I cells (BJAB), both the receptor and the mitochondrial pathway were activated upon drug treatment, since blockade of either the receptor pathway by overexpression of dominant negative FADD (FADD-DN) or of the mitochondrial pathway by overexpression of Bcl-X(L) only partially inhibited apoptosis. Drug treatment induced formation of a FADD- and caspase-8-containing CD95 death-inducing signaling complex (DISC) in type I cells resulting in activation of caspase-8 as the most apical caspase. In contrast, in type II cells (Jurkat), apoptosis was predominantly controlled by mitochondria, since overexpression of Bcl-2 completely blocked drug-induced apoptosis, while overexpression of FADD-DN had no protective effect. In these cells, caspases including caspase-8 were activated by mitochondria-driven signaling events and no DISC was detected despite expression levels of CD95, FADD and caspase-8 proteins comparable to type I cells. Likewise, drug-induced CD95 aggregation was predominantly found in type I cells. Bid was cleaved prior to mitochondrial alterations in type I cells providing a molecular link between caspase-8 activation and mitochondrial perturbations, whereas in type II cells, Bid was cleaved downstream of mitochondria. Our findings of a cell type specific response to cytotoxic drugs have implications for the identification of molecular parameters for chemosensitivity or resistance in different tumor cells.
- Published
- 2001
- Full Text
- View/download PDF
32. Autoamplification of apoptosis following ligation of CD95-L, TRAIL and TNF-alpha.
- Author
-
Herr I, Posovszky C, Di Marzio LD, Cifone MG, Boehler T, and Debatin KM
- Subjects
- Activating Transcription Factor 2, Antibodies, Monoclonal pharmacology, Apoptosis Regulatory Proteins, Cyclic AMP Response Element-Binding Protein metabolism, Fas Ligand Protein, Fatty Acid Desaturases deficiency, Fatty Acid Desaturases physiology, Gene Expression Regulation, Neoplastic drug effects, Humans, JNK Mitogen-Activated Protein Kinases, Jurkat Cells, Ligands, Membrane Glycoproteins biosynthesis, Membrane Glycoproteins genetics, Mitogen-Activated Protein Kinases metabolism, Neoplasm Proteins physiology, Phosphorylation drug effects, Promoter Regions, Genetic, Protein Processing, Post-Translational drug effects, Proto-Oncogene Proteins c-jun metabolism, Receptors, Tumor Necrosis Factor drug effects, Receptors, Tumor Necrosis Factor physiology, Recombinant Fusion Proteins pharmacology, TNF-Related Apoptosis-Inducing Ligand, Transcription Factors metabolism, Transcription, Genetic drug effects, Tumor Necrosis Factor-alpha biosynthesis, Tumor Necrosis Factor-alpha genetics, fas Receptor physiology, p38 Mitogen-Activated Protein Kinases, Apoptosis drug effects, Arabidopsis Proteins, Autocrine Communication physiology, Gene Expression Regulation drug effects, Membrane Glycoproteins physiology, Signal Transduction drug effects, Tumor Necrosis Factor-alpha physiology
- Abstract
CD95-L, TNF-alpha and TRAIL are death-inducing ligands (DILs) which may signal apoptosis via crosslinking of their cognate receptors. The present study shows that treatment of cells with agonistic mAB alpha APO-1 (CD95), recombinant TRAIL or TNF-alpha leads to enhanced mRNA and protein expression of each DIL with concomitant death in target cells. Immunoprecipitation of CD95-L protein from supernatant as well as neutralizing antibodies suggest DIL proteins to be cooperatively acting mediators of these cytotoxic activity. Autoamplification of the death signal was blocked in cells with a defect in apoptosis signaling either due to a dysfunctional FADD molecule or to the failure to activate JNK/SAPKs. Phosphorylation and enhanced binding of cJun and ATF-2 to DIL promoters suggest JNK/SAPKs as activators of these transcription factors following death receptor triggering. In consequence, autocrine production of DILs allows the spread of death signals to sensitive target cells. Oncogene (2000) 19, 4255 - 4262
- Published
- 2000
- Full Text
- View/download PDF
33. MycN sensitizes neuroblastoma cells for drug-induced apoptosis.
- Author
-
Fulda S, Lutz W, Schwab M, and Debatin KM
- Subjects
- Caspase 3, Caspase 8, Caspase 9, Caspases metabolism, Cisplatin toxicity, Doxorubicin toxicity, Enzyme Activation, Humans, Mitochondria drug effects, Mitochondria physiology, Proto-Oncogene Proteins biosynthesis, Tumor Cells, Cultured, Tumor Suppressor Protein p53 biosynthesis, bcl-2-Associated X Protein, fas Receptor metabolism, Apoptosis, Neuroblastoma pathology, Proto-Oncogene Proteins c-bcl-2, Proto-Oncogene Proteins c-myc metabolism
- Abstract
Amplification of the MYCN gene is found in a large proportion of neuroblastoma and considered as an adverse prognostic factor. To investigate the effect of ectopic MycN expression on the susceptibility of neuroblastoma cells to cytotoxic drugs we used a human neuroblastoma cell line harboring tetracycline-controlled expression of MycN. Neither conditional expression of MycN alone nor low drug concentrations triggered apoptosis. However, when acting in concert, MycN and cytotoxic drugs efficiently induced cell death. Apoptosis depended on mitochondrial permeability transition and activation of caspases, since the mitochondrion-specific inhibitor bongkrekic acid and the caspase inhibitor zVAD-fmk almost completely abrogated apoptosis. Loss of mitochondrial transmembrane potential and release of cytochrome c from mitochondria preceded activation of caspase-8 and caspase-3 and cleavage of PARP. CD95 expression was upregulated by treatment with cytotoxic drugs, while MycN cooperated with cytotoxic drugs to increase sensitivity to CD95-induced apoptosis and enhancing CD95-L expression. MycN overexpression and cytotoxic drugs also synergized to induce p53 and Bax protein expression, while Bcl-2 and Bcl-X(L) protein levels remained unchanged. Since amplification of MYCN is usually associated with a poor prognosis, these findings suggest that dysfunctions in apoptosis pathways may be a mechanism by which MycN-induced apoptosis of neuroblastoma cells is inhibited.
- Published
- 1999
- Full Text
- View/download PDF
34. MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells.
- Author
-
Lutz W, Fulda S, Jeremias I, Debatin KM, and Schwab M
- Subjects
- Antigens, CD biosynthesis, Apoptosis drug effects, Carrier Proteins biosynthesis, Cell Line, DNA Primers, Gene Amplification, Humans, Membrane Proteins biosynthesis, Neuroblastoma, Polymerase Chain Reaction, Proto-Oncogene Proteins biosynthesis, Proto-Oncogene Proteins c-bcl-2 metabolism, RNA, Messenger biosynthesis, Signal Transduction, Transcription, Genetic, Tumor Cells, Cultured, bcl-2 Homologous Antagonist-Killer Protein, bcl-2-Associated X Protein, bcl-Associated Death Protein, fas Receptor biosynthesis, Apoptosis physiology, Genes, myc, Interferon-gamma pharmacology, Proto-Oncogene Proteins c-myc biosynthesis
- Abstract
Neuroblastomas undergo spontaneous regression at an unusually high rate. The mechanisms are not clear, but apoptosis may be involved. A large proportion of neuroblastomas is characterized by amplification of MYCN. Using human neuroblastoma cells harbouring tetracycline controlled expression of MYCN we have analysed the role of the MycN protein and IFNgamma in cell death decision. Neither conditional expression of MYCN nor treatment with IFNgamma alone was sufficient to trigger cell death. However, when acting in concert MycN and IFNgamma efficiently triggered cell death, which was accompanied by DNA fragmentation and required caspase activity, two hallmarks of apoptosis. MycN and IFNgamma may cooperate along at least two different pathways. First, IFNgamma increased the CD95 cell surface expression while MycN enhanced the cellular susceptibility for the CD95 mediated death signal. Second, IFNgamma treatment induced expression of BAK mRNA while MycN and IFNgamma in combination increased the amount of Bax protein, another activator of apoptosis, without a concomitant increase in BAX mRNA. MycN also increased cell death in response to TRAIL and TNFalpha, suggesting that enforced MYCN expression in general increases the susceptibility of neuroblastoma cells towards a variety of death stimuli.
- Published
- 1998
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.